News

Filter

Current filters:

PricingBiosimilars

1 to 9 of 10 results

Spain to reduce the prices of new biosimilars by up to 30%

Spain to reduce the prices of new biosimilars by up to 30%

12-03-2015

After months of uncertainty, the Spanish Ministry of Health has announced its new policy for the biosimilars…

BiosimilarsBiotechnologyinfliximabPoliticsPricingSpain

Japan Pharma outlook 2015

Japan Pharma outlook 2015

06-03-2015

The new pricing system adopted in Japan from April 2014 is a game changer initiative. It pains most of…

BiosimilarsGenericsJapanMarkets & MarketingPricing

Biobetters plugging gap in the biosimilar market for growth hormone deficiency

Biobetters plugging gap in the biosimilar market for growth hormone deficiency

25-02-2015

Although there appears to be a gap in the market for biosimilars in growth hormone deficiency indications,…

BiosimilarsGeneticsGlobalDataPricingProduction

PHARMAC secures significant savings for New Zealand’s DHBs on biologic drug

04-12-2014

A new agreement for a high cost biologic drug will yield considerable savings for District Health Boards…

Anti-Arthritics/RheumaticsBiosimilarsBiotechnologyinfliximabJohnson & JohnsonNew ZealandPricingRemicade

Polish and European generics groups view opportunities for biosimilars

29-10-2014

The European Biosimilars Group – a sector group of the European Generic medicines Association, together…

BiosimilarsEastern EuropeGenericsMarkets & MarketingPolandPricingRegulation

Targeted therapies must show cost effectiveness to compete with biosimilars in Brazil and Mexico

Targeted therapies must show cost effectiveness to compete with biosimilars in Brazil and Mexico

10-06-2014

Certain targeted therapies enjoy extensive but incomplete coverage in Brazil and Mexico through complex…

BiosimilarsBrazilJohnson & JohnsonMabTheraMexicoOncologyPharmaceuticalPricingRocheVelcade

Fast growth forecast for South Korean pharma market

Fast growth forecast for South Korean pharma market

02-04-2014

South Korea's pharmaceuticals market was valued at $20 billion in 2012, growing from $14.5 billion in…

Asia-PacificBiosimilarsBiotechnologyMarkets & MarketingPricingResearch

1 to 9 of 10 results

Back to top